Linked Life Data

8210698

Source:http://linkedlifedata.com/resource/pubmed/id/8210698

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1993-11-18
pubmed:abstractText
Fetal glucocorticoid administration has been proposed to elicit both promotional and inhibitory effects on neuronal development. In the current study, pregnant rats were given 0.05, 0.2 or 0.8 mg/kg of dexamethasone on gestational days 17, 18 and 19, and the effects on development of central cholinergic projections was assessed on postnatal day 1 by measuring the specific binding of [3H]hemicholinium-3 to the high affinity choline transporter localized in cholinergic nerve terminal membranes. Dexamethasone produced a dose-dependent retardation of brain region growth, but enhanced [3H]hemicholinium-3 binding in both the forebrain and the midbrain + brainstem. At the highest dose, the promotional effect on [3H]hemicholinium-3 binding was lost in the forebrain, a region that is particularly sensitive during late gestation to inhibitory effects of glucocorticoids on neuronal development. These results indicate that, even in the face of growth retardation, glucocorticoids promote the development of central cholinergic projections; however, at high doses, inhibitory actions of the steroid can offset the promotional effects in some regions.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0034-5164
pubmed:author
pubmed:issnType
Print
pubmed:volume
81
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
191-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Dexamethasone treatment in utero enhances neonatal cholinergic nerve terminal development in rat brain.
pubmed:affiliation
Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27710.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S.